Network
Researcher and doctor Dr. Jacob Wesley Ulm, MD, Ph.D. as quoted by Media Magelang said the issue of which type of vaccine is right for people with congenital diseases is still a matter of debate.
"Which vaccine is suitable for people with diabetes, for example? This is not a question with a straightforward answer because although Pfizer BioNTech's level of efficacy is high, it is not clear how it will affect each individual," said the doctor who admitted that he had experienced COVID-19 symptoms at the beginning of the pandemic.
With the faster spread of the Delta variant, for practical purposes, J&J or Sinopharm vaccines could be the option since they do not require extra cold storage such as mRNA vaccines as used for the Pfizer vaccine.
“All of the vaccines on the market have confirmed good safety and efficacy profiles, but their effects and suitability for any given individual with a comorbidity can be difficult to be certain of. Given the rampant, rapid, and widespread dissemination of the dangerous Delta variant, furthermore, considerations of sheer logistics must be taken into account. Thus, vaccines that are easier to manufacture, ship, and store--for example the Sinopharm, J&J, AZ, and Sputnik vaccines, which do not require the ultra-cold storage and delivery of the Biotech-Pfizer and Moderna vaccines--may in practice be better options on a mass scale, even if the mRNA vaccines might be, technically, more efficacious in a given diabetes patient cohort. The same will likely be true of the protein-subunit vaccines--Novavax and Sanofi--when they become available. At this point, given the mounting threat and alarming contagiousness of the Delta variant (B.1.617.2), the goal should be ensuring ample supplies of whatever vaccine is most available,” the expert said.
However, further clinical trials are still needed involving people with comorbidities, such as people with diabetes and other diseases.
In conclusion, the current vaccine is the best to protect us and those around us from being exposed to Covid-19.
The level of efficacy of the Covid-19 vaccine is important but not the only determining factor.***
